Cas:784-50-9 9-Oxo-9H-fluorene-2-carboxylic acid manufacturer & supplier

Chemical Name:9-Oxo-9H-fluorene-2-carboxylic acid

CAS.NO:784-50-9

Synonyms:9-Oxo-9H-fluorene-2-carboxylic acid;9-oxofluorene-2-carboxylic acid;9H-Fluorene-2-carboxylic acid, 9-oxo-;EINECS 212-317-3;MFCD00001156

Molecular Formula:C₁₄H₈O₃

Molecular Weight:224.212

HS Code:2918300090

Physical and Chemical Properties:

Melting point:>300 °C(lit.)

Boiling point:476.5±24.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.701

PSA:54.37000

Exact Mass:224.047348

LogP:3.26

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 9-Oxo-9H-fluorene-2-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00001156 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00001156 Use and application,9H-Fluorene-2-carboxylic acid, 9-oxo- technical grade,usp/ep/jp grade.

Related News: The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. 9-Oxo-9H-fluorene-2-carboxylic acid manufacturer The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 9-Oxo-9H-fluorene-2-carboxylic acid supplier The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 9-Oxo-9H-fluorene-2-carboxylic acid vendor The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured. 9-Oxo-9H-fluorene-2-carboxylic acid factory The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market.